1918

Servikovajinal Pap-Smear Test Sonucu Atrofi Olan Hastaların Klinik Özelliklerinin Değerlendirilmesi

Amaç: Serviksteki prekanseröz değişiklikleri saptamak için kullanılan Pap-smear testi hormonal durum hakkında da bilgi verebilir. Vajinal atrofi kadınlarda birçok şikâyete sebep olarak yaşam kalitesini etkileyebilir. Çalışmada Pap-smear testinde atrofi saptanan hasta grubunda yaş, semptom, menopoz durumu ve ultrasonografi ile ölçülen endometrial kalınlık ilişkisini incelemek amaçlandı. Gereç ve Yöntemler: Pap-smear testi yapılıp sonucunda atrofi saptanan hastalar çalışmaya alındı. Hastaların yaş, semptom, menopoz durumu ve ultrasonografi ile ölçülen endometrial kalınlıkları dosyalardan taranarak elde edildi ve aralarındaki ilişki istatistiksel olarak incelendi. Bulgular: Toplam 408 hastanın 86’sında (%21,1) semptom görüldü. En sık görülen semptomun disüri ve üriner inkontinans olduğu saptandı. Semptomları olanların yaş ortalaması 55,8±10,9 iken, semptomları olmayanların yaş ortalaması 53,2±9,9 idi ve aralarında anlamlı fark vardı (p=0.038). Menopozda olan hastaların 70’inde (%23,7) semptom görülürken, menopozda olmayan hastaların 16’sında (%14,2) semptom görüldü. Menopozda olan hastalarda olmayanlara göre istatistiksel olarak anlamlı bir şekilde semptomların daha fazla olduğu görüldü (p=0.041). Postmenopozal dönemde olan hastalarda ultrasonografi ile ölçülen endometrial kalınlık ortalaması, semptomu olmayanlarda 4,74±3,64 iken semptomu olan hastalarda 3,54±1,17 idi. Aralarında istatistiksel olarak anlamlı fark saptandı (p

Evaluation of Clinical Features of Patients with Atrophic Cervicovaginal Pap-Smear Results

Aim: The Pap-smear test used to detect precancerous changes in the cervix, can also provide information about the hormonal status. Vaginal atrophy can affect the quality of life by causing many complaints in women. In the study, it was aimed to investigate the relationship between age, symptom, menopausal status and endometrial thickness measured by ultrasonography in the patient group with atrophy in the Pap-smear test. Material and Methods: Patients with atrophy as a result of Pap-smear test were selected. Patients’ age, symptoms, menopause status and endometrial thicknesses measured by ultrasonography were obtained from the patient files and the relationship between them was analyzed statistically. Results: Symptoms were seen in 86 (21.1%) of 408 patients. The most common symptom was dysuria, urinary incontinence. The mean age of patients with symptoms was 55.8 ± 10.9, while the mean age of patients without symptoms was 53.2 ± 9.9, and there was a significant difference between them (p = 0.038). Symptoms were seen in 70 (23.7%) of postmenopausal women, and 16 (14.2%) of premenopausal women. Postmenopausal women had statistically significant more symptoms compared to premenopausal women (p = 0.041). In postmenopausal women, the mean endometrial thickness measured by ultrasonography was 4.74 ± 3.64 in patients without symptoms, while it was 3.54 ± 1.17 in patients with symptoms. There was a statistically significant difference between them (p

PDF

___

1. Lauritzen C. Basic facts and definitions. In: Lauritzen C, Studd J, editors. Current management of the menopause, London: Taylor & Francis; 2005. 3–8
2. Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA. Genitourinary syndrome of menopause: An overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 2016;215:704–711.
3. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 2013;20:162–168.
4. Robinson D, Cardozo L. Estrogens and urogenital atrophy. In: Lauritzen C, Studd J, editors. Current management of the menopause, London: Taylor & Francis; 2005. 205–218.
5. Crothers BA, Booth CN, Darragh TM, Means MM, Souers RJ, Thomas N, Moriarty AT. Atrophic vaginitis: Concordance and interpretation of slides in the College of American Pathologists Cervicovaginal Interlaboratory Comparison Program in Gynecologic Cytopathology. Arch Pathol Lab Med 2012;136(11):1332-1338.
6. Alvisi S, Gava G, Orsili I, Giacomelli G, Baldassarre M, Seracchioli R, Meriggiola MC. Vaginal health in menopausal women. Medicina (Kaunas) 2019;55(10):615.
7. Şahin B , Güner E , Kara O . The evaluation of colposcopic examinations and cervical histopathology results of women with abnormal pap-smear and/or hpv positivity: A sample from amasya. Batı Karadeniz Tıp Dergisi 2020;4(3):142-149.
8. Repse-Fokter A, Takac I, Fokter SK. Postmenopausal vaginal atrophy correlates with decreased estradiol and body mass index and does not depend on the time since menopause. Gynecol Endocrinol 2008;24(7):399-404.
9. Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S. Symptoms in the menopausal transition: Hormone and behavioral correlates. Obstet Gynecol 2008;111(1):127–136.
10. Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health 2018;10:387-395.
11. Gass ML, Cochrane BB, Larson JC, Manson JE, Barnabei VM, Brzyski RG, Lane DS, LaValleur J, Ockene JK, Mouton CP, Barad DH. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women’s Health Initiative. Menopause 2011;18(11):1160–1171.
12. Domoney C. Treatment of vaginal atrophy. Womens Health (Lond) 2014;10(2):191-200.
13. Nappi RE, Kokot-Kierepa M. Vaginal health: Insights, views and attitudes (VIVA) – results from an international survey. Climacteric 2012;15(1):36–44.
14. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE (Real Womens Views of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013;10(7):1790–1799.
15. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 2007;14:168–182.
16. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6(8):2133– 2142.
17. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: A synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-1543.
18. Jamal H, Saygılı H, Akhan SE, Kartal A, et al. Asemptomatik postmenopozal kadınlarda periferik androjenlerin, seks hormonu bağlayıcı globülinin ve vücut kitle indeksinin ultrasonografide endometrium kalınlığına etkileri. İstanbul Tıp Dergisi 2004;4:13-9.